Efficient exon skipping by base-editor-mediated abrogation of exonic splicing enhancers

Cell Rep. 2023 Nov 28;42(11):113340. doi: 10.1016/j.celrep.2023.113340. Epub 2023 Oct 30.

Abstract

Duchenne muscular dystrophy (DMD) is a severe genetic disease caused by the loss of the dystrophin protein. Exon skipping is a promising strategy to treat DMD by restoring truncated dystrophin. Here, we demonstrate that base editors (e.g., targeted AID-mediated mutagenesis [TAM]) are able to efficiently induce exon skipping by disrupting functional redundant exonic splicing enhancers (ESEs). By developing an unbiased and high-throughput screening to interrogate exonic sequences, we successfully identify novel ESEs in DMD exons 51 and 53. TAM-CBE (cytidine base editor) induces near-complete skipping of the respective exons by targeting these ESEs in patients' induced pluripotent stem cell (iPSC)-derived cardiomyocytes. Combined with strategies to disrupt splice sites, we identify suitable single guide RNAs (sgRNAs) with TAM-CBE to efficiently skip most DMD hotspot exons without substantial double-stranded breaks. Our study thus expands the repertoire of potential targets for CBE-mediated exon skipping in treating DMD and other RNA mis-splicing diseases.

Keywords: CP: Genomics; CRISPR; DMD; base editor; exon skipping; exonic splicing enhancer; gene therapy; genome editing; muscular dystrophy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Dystrophin* / genetics
  • Dystrophin* / metabolism
  • Exons / genetics
  • Humans
  • Muscular Dystrophy, Duchenne* / genetics
  • Muscular Dystrophy, Duchenne* / metabolism
  • RNA Splicing / genetics
  • RNA, Guide, CRISPR-Cas Systems

Substances

  • Dystrophin
  • RNA, Guide, CRISPR-Cas Systems